Aug 23, 2023Etcembly's T-cell engager featured in Inside Precision MedicineThe announcment of Etcembly's picomolar affinity bispecific T-cell engager targeting PRAME, ETC-101, has been covered by inside Precision...
Dec 14, 2022Etcembly announces breakthrough in optimising TCR assetsEtcembly Announces Breakthrough in Optimising TCR Assets. Successful Financing Brings in Singapore VC iGlobe Partners.
Mar 15, 2022Etcembly Appoints Scott Cuthill as Chief Business OfficerEtcembly Appoints Scott Cuthill as Chief Business Officer. The Oxford based company is transforming TCR immunotherapy research.
Feb 7, 2022Research Complex at Harwell welcomes EtcemblyResearch Complex at Harwell is delighted to welcome Etcembly. The company is continuing to expand to realise its goal to assemble the...
Feb 7, 2022Etcembly establishes new lab & office space at Oxford Science ParkImmune-focused machine learning firm joins leading AI cohort on Park Etcembly Ltd has moved into more than 1,000 square feet of new...
Feb 7, 2022Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly LimitedOslo, Norway and Oxford, UK: 29th April 2021. Zelluna Immunotherapy AS announces an exclusive research collaboration with Etcembly Ltd to...
Feb 7, 2022Oxford-based machine learning start-up Etcembly secures Private Seed FundingOxford, UK: 23rd April 2021. No embargo. Etcembly Ltd (Etcembly), a company building a platform to decode immune repertoires in health...